Comparative Pharmacology
Head-to-head clinical analysis: HYDROPRES 50 versus VISKAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROPRES 50 versus VISKAZIDE.
HYDROPRES 50 vs VISKAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine is a rauwolfia alkaloid that depletes catecholamines and serotonin from central and peripheral nerve endings, reducing sympathetic outflow and lowering blood pressure. The combination provides additive antihypertensive effect.
Viskazide is a combination of pindolol (a non-cardioselective beta-blocker with intrinsic sympathomimetic activity) and hydrochlorothiazide (a thiazide diuretic). Pindolol competitively blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule, decreasing sodium and water reabsorption, leading to reduced plasma volume and blood pressure.
HYDROPRES 50 is a fixed-dose combination of hydrochlorothiazide 50 mg and reserpine 0.125 mg. Usual adult dose: one tablet orally once daily.
Oral: 1 tablet (pindolol 10 mg / hydrochlorothiazide 25 mg) once daily; may increase to 2 tablets once daily if needed.
None Documented
None Documented
Hydrochlorothiazide: 6-15 hr (terminal); Reserpine: 50-100 hr (terminal, biphasic). Clinical: HCTZ half-life prolonged in renal impairment; reserpine accumulates with repetitive dosing.
Terminal elimination half-life is 10-12 hours for the hydrochlorothiazide component and 4-6 hours for pindolol; clinical context: steady-state achieved in 2-3 days for pindolol and 3-5 days for hydrochlorothiazide.
Hydrochlorothiazide: 95% renal (65% unchanged); Reserpine: 30% renal, 60% fecal
Renal elimination (approximately 70% unchanged), with the remainder as inactive metabolites; biliary/fecal excretion is minor (<10%).
Category C
Category C
Thiazide Diuretic Combination
Beta Blocker/Thiazide Diuretic Combination